Filter by
Filter by
Long-term outcomes of high-dose (74 GyE) proton beam therapy with concurrent chemotherapy for stage III nonsmall-cell lung cancer.
This study reported outcomes of 45 patients with stage III NSCLC treated with PBT of 74 GyE and concurrent chemotherapy. With a median follow-up time of 42.1...
Exposure of the heart in lung cancer radiation therapy: A systematic review of heart doses published during 2013 to 2020.
Data of 140 dosimetry studies was analyzed. In the 105 non-SABR studies, the average MHD was similar between IMRT and 3DCRT (10.9 Gy versus 10.6 Gy) and lower...
ASTRO Radiation Therapy Summary of the ASCO Guideline on Management of Stage III Non-Small Cell Lung Cancer.
Based on the ‘Management of Stage III Non-Small-Cell Lung Cancer: ASCO Guideline’, this summary document makes recommendations directly related to RT for the...
Future Perspectives of Proton Therapy in Minimizing the Toxicity of Breast Cancer Radiotherapy.
A review article compared the clinical evidence including the parameters of the dose distribution in organs at risk, such as the heart, blood vessels, and lungs...
A retrospective study of adjuvant proton radiotherapy for breast cancer after lumpectomy: a comparison of conventional-dose and hypofractionated dose.
Fifty patients were treated with PT using two different regimens following lumpectomy. 14 patients received IMPT to a total dose of 50 Gy in 25 fractions...
Radiation-induced skin and heart toxicity in patients with breast cancer treated with adjuvant proton radiotherapy: a comparison with photon radiotherapy.
The active and inactive (pro-BNP and NT-proBNP) forms of BNP are classically used as biomarkers for diagnosing and monitoring acute and chronic heart failure...